PRIMAEGISresearch
← Scenarios
VIYASH

Viyash Scientific Limited

Pharmaceuticals: Major/ NSE
Screener TradingView
Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target
VIYASH
FY26 → FY28 · 2 years of guidance · ~1.7 years from today₹252 today
BEAR
₹173
-31%-20% a yr
8.5% a year · 36.1x exit
BASE
₹306
+22%+12% a yr
14.8% a year · 57.2x exit
BULL
₹696
+176%+84% a yr
20.1% a year · 118.8x exit
FY27FY28TODAY₹252 today₹696₹173₹306
Where the market has priced it
4x62x today146x
  • FY26 earnings of Rs 4.06 sit 4x the prior year (Rs 0.93) and 4x the median of the years before it — a discontinuity, not a run-rate this projection can assume continues
  • the guided figure reached earnings through a low-confidence bridge
  • the last 2 years priced this company 69% above its ten-year median (97x vs 57x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
  • this company's own median multiple sits 101% above its filed-industry peers; the scenario uses its own
How these numbers are produced
Earnings baseFY26 fiscal year EPS ₹4.06 (screener)
Guided growth14.8% a year, said on the call of 09-Feb-2026 · transcript
Read across asoperating: unlabelled growth figure, read as revenue — low confidence
Delivery calibration0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple36.15x / 57.21x / 118.84x, this company’s own p20 / median / p80 across 7 filed years
Filed-industry peersmedian 28.43x across 38 peers — the cross-check, not the input
Arithmeticbase EPS × (1 + guided growth × delivery)2 × exit multiple
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

What management said

from NSE earnings-call filings · extracted, not interpreted
generic growth 15%ebitda growth 20%
So, when we say INR 185 crores this quarter, INR 187 crores last quarter, and also the topline is going to close to INR 900 crores, INR 860 odd crores or even if you take 15% growth we are pretty comfortable to reach that level, not even FY
Call 09-Feb-2026 · bridge confidence low · transcript PDF